These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3127585)

  • 41. Follow-up with OM-8980 after a double-blind study of OM-8980 and auranofin in rheumatoid arthritis.
    Vischer TL
    Clin Rheumatol; 1990 Sep; 9(3):356-61. PubMed ID: 2261735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis. The European Multicentre Study Group.
    Lemmel EM
    Br J Rheumatol; 1993 May; 32(5):375-82. PubMed ID: 8495257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples.
    Feeny DH; Torrance GW
    Med Care; 1989 Mar; 27(3 Suppl):S190-204. PubMed ID: 2522159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of auranofin on lymphocyte membrane fluidity in rheumatoid arthritis. A fluorescence polarization study.
    Beccerica E; Piergiacomi G; Curatola G; Ferretti G
    Scand J Rheumatol; 1989; 18(6):413-8. PubMed ID: 2617230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methods of assessing the effect of drug therapy on quality of life.
    Ganz PA
    Drug Saf; 1990; 5(4):233-42. PubMed ID: 2198049
    [No Abstract]   [Full Text] [Related]  

  • 46. Auranofin in rheumatoid arthritis: what variables could affect the clinical response?
    Harth M
    Agents Actions Suppl; 1988; 24():167-77. PubMed ID: 3055876
    [No Abstract]   [Full Text] [Related]  

  • 47. Auranofin. The Pharmacy Department, the Amalgamated Melbourne and Essendon Hospitals.
    Aust Nurses J; 1988 Jun; 17(11):25-6. PubMed ID: 3421870
    [No Abstract]   [Full Text] [Related]  

  • 48. Economic assessments in randomized controlled trials.
    Bulpitt CJ; Fletcher AE
    Med J Aust; 1990 Aug; 153(S1):S16-9. PubMed ID: 2116582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Auranofin: a new drug for rheumatoid arthritis.
    Ann Intern Med; 1987 Apr; 106(4):631-2. PubMed ID: 3826966
    [No Abstract]   [Full Text] [Related]  

  • 50. Auranofin, methotrexate, but no placebo: comment on the article by Williams et al.
    Epstein WV; Criswell LA
    Arthritis Rheum; 1992 Nov; 35(11):1406-7. PubMed ID: 1445469
    [No Abstract]   [Full Text] [Related]  

  • 51. Issues in therapeutic apheresis.
    Berkman E
    N Engl J Med; 1982 Jun; 306(23):1418-20. PubMed ID: 6804867
    [No Abstract]   [Full Text] [Related]  

  • 52. Lymphapheresis in rheumatoid arthritis. A randomized trial.
    Karsh J; Klippel JH; Plotz PH; Decker JL; Wright DG; Flye MW
    Arthritis Rheum; 1981 Jul; 24(7):867-73. PubMed ID: 7020704
    [No Abstract]   [Full Text] [Related]  

  • 53. No firm basis to advocate auranofin in the treatment of juvenile rheumatoid arthritis.
    Criswell LA; Katz PP; Tack BB
    Arthritis Rheum; 1991 Jul; 34(7):934-5. PubMed ID: 1898455
    [No Abstract]   [Full Text] [Related]  

  • 54. Blinding of clinical trials with concurrent economic analysis.
    Johnson K
    JAMA; 1997 Jun; 277(21):1677. PubMed ID: 9169884
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study.
    Devji T; Carrasco-Labra A; Qasim A; Phillips M; Johnston BC; Devasenapathy N; Zeraatkar D; Bhatt M; Jin X; Brignardello-Petersen R; Urquhart O; Foroutan F; Schandelmaier S; Pardo-Hernandez H; Vernooij RW; Huang H; Rizwan Y; Siemieniuk R; Lytvyn L; Patrick DL; Ebrahim S; Furukawa T; Nesrallah G; Schünemann HJ; Bhandari M; Thabane L; Guyatt GH
    BMJ; 2020 Jun; 369():m1714. PubMed ID: 32499297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rheumatoid arthritis and sexuality: a patient survey in France.
    Kobelt G; Texier-Richard B; Mimoun S; Woronoff AS; Bertholon DR; Perdriger A; Maugars Y; Combe B
    BMC Musculoskelet Disord; 2012 Sep; 13():170. PubMed ID: 22963081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thoughts on health economics in rheumatoid arthritis.
    Kobelt G
    Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii35-9. PubMed ID: 17934092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How can quality of life researchers make their work more useful to health workers and their patients?
    Guyatt G; Schunemann H
    Qual Life Res; 2007 Sep; 16(7):1097-105. PubMed ID: 17530444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
    Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.
    Brozek JL; Guyatt GH; Schünemann HJ
    Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.